The global anti-bleeding drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The anti-bleeding drugs are the drugs that prevent coagulation of blood by prolonging the clotting time. The rise in the number of road traffic injuries across the globe is anticipated to fuel the demand such drugs, which in turn will further drive the growth of the global anti-bleeding drug market. For instance, according to the data published by World Health Organization in 2021, road traffic injuries are the leading cause of mortalities in children and young adults aged 5-29 years and about 73.0% of all road traffic injuries occur among young males under the age of 25 years. Approximately 1.3 million mortalities occur annually as a result of road traffic crashes. More than 90.0% of the world’s fatalities on the roads occur in low – and middle-income countries. Moreover, an estimated 20 million – 50 million people suffer from non-fatal injuries, with many incurring a disability as a result of their injury.
A full report of Wooden Decking Market is available at:https://orionmarketreports.com/global-anti-bleeding-drug-market/92818/
Looking towards the demand for anti-bleeding drugs, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Bayer AG had received the USFDA approval of Xarelto for the treatment of Venous Thromboembolism (VTE). Further, the drug assists to reduce the risk of recurrent VTE in patients from birth to less than 18 years at least at 5 days of initial parenteral anticlougant treatment. In December 2020, Natco Pharma Ltd had announced the launch of the Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticlougant medication used to treat and prevent blood clots.
In June 2021, the USFDA has approved Pradaxa (dabigatran etexilate) oral pallets to treat children 3months to less than 12 years old with venous blood clots, post-treatment with blood thinner given by injection for at least five days. Therefore, such approvals coupled with product launches are anticipated to drive the growth of the global anti-bleeding drug market during the forecast period.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Baxter International, Inc., Pfizer Inc., and Johnson & Johnson Services Inc among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Anti Bleeding drug Market Report by Segment
By Type
- Collagen
- Oxidized Regenerated Cellulose
- Gelatin
- Polysaccharide
By Application
- Hospitals
- Clinics
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
